RANBP3

Across TCGA pan-cancer cohorts, RANBP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RANBP3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RANBP3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RANBP3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RANBP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.709	0.937	<.001	79	view →
PDAC	DFS	Quartile	All	0.891	0.632	.003	35	view →
LUAD	DFS	Tertile	All	0.782	0.512	.013	11	view →
CCRCC	OS	Tertile	II,III,IV	0.884	0.579	.014	10	view →
UCEC	DFS	Median	All	0.932	0.798	.047	2	view →
LSCC	DFS	Median	All	0.885	0.524	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RANBP3–HNSC (OS)

Open the HNSC breakdown →